Yonglong Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yonglong Zhong has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Lingyu Jiang
The First Affiliated Hospital, Jinan University, Guangzhou 510006, PR China
5 shared publicationsZhaoke Wen
Department of Thoracic Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning 530021, PR China
5 shared publications- Hui Lin
Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning 530021, Guangxi, Peoples R China
4 shared publications Baijun Li
Department of Thoracic Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
2 shared publications- Baijun Li
Department of Thoracic Cardiovascular Surgery, the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning, 530021, P.R. China.
2 shared publications Xiangwei Li
Department of Thoracic Cardiovascular Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region, China
2 shared publications
Latest Publications
- Open Access
- 8 June 2022
- Published by Springer Nature in Research Square
A novel glutamine metabolism-related gene signature for prognostic prediction in patients with lung adenocarcinoma
Background Lung adenocarcinoma (LUAD) is the major non-small-cell lung cancer pathological subtype with poor prognosis worldwide. Glutamine metabolism (GM) plays an important role in tumor development and progression. Herein, we aimed to construct a GM-associated prognostic gene signature to predict survival in patients with LUAD. Methods The gene expression profiles of patients with LUAD were downloaded from the Cancer Genome Atlas (TCGA), and two independent datasets for validation were downloaded from the Gene Expression Omnibus (GEO). 41 GM-related genes were downloaded from the previous literatures and used to establish GM-related risk model (names as Score). The prognostic GM-associated gene signatures were identified using univariate Cox and LASSO analyses. Kaplan-Meier and receiver operating characteristic (ROC) curves were performed to validate the predictive efficacy of the prognostic signatures. The correlation between the GMScore and tumor-infiltrated immune cells was evaluated using CIBERSORTx analysis. A nomogram was used to predict the survival probability of LUAD based on GMScore. Results We constructed a prognostic signature comprising 7 GM-related genes (AMDHD1, GAPDH, GCLC, GLS2, HAL, SLC38A2, SLC7A5). The Kaplan-Meier curves validated the reliable predictive ability of the prognostic signature in TCGA and two GEO datasets (p < 0.001, p = 0.001, and p = 0.003, respectively). The area under the curve (AUC) of the ROC curves validated the predictive accuracy of the risk model. We constructed a nomogram to predict the survival probability of LUAD, and the calibration curves showed well predictive accuracy. Finally, functional analysis also revealed distinct immune status between high and low GMScore groups in LUAD. Conclusion Our study constructed a GM-related gene signature, and indicated that GMScore could serve as a novel biomarker for predicting patients' survival in LUAD.
- 8 June 2022
- Published by Springer Nature in Research Square
Open AccessA novel glutamine metabolism-related gene signature for prognostic prediction in patients with lung adenocarcinoma
Background Lung adenocarcinoma (LUAD) is the major non-small-cell lung cancer pathological subtype with poor prognosis worldwide. Glutamine metabolism (GM) plays an important role in tumor development and progression. Herein, we aimed to construct a GM-associated prognostic gene signature to predict survival in patients with LUAD. Methods The gene expression profiles of patients with LUAD were downloaded from the Cancer Genome Atlas (TCGA), and two independent datasets for validation were downloaded from the Gene Expression Omnibus (GEO). 41 GM-related genes were downloaded from the previous literatures and used to establish GM-related risk model (names as Score). The prognostic GM-associated gene signatures were identified using univariate Cox and LASSO analyses. Kaplan-Meier and receiver operating characteristic (ROC) curves were performed to validate the predictive efficacy of the prognostic signatures. The correlation between the GMScore and tumor-infiltrated immune cells was evaluated using CIBERSORTx analysis. A nomogram was used to predict the survival probability of LUAD based on GMScore. Results We constructed a prognostic signature comprising 7 GM-related genes (AMDHD1, GAPDH, GCLC, GLS2, HAL, SLC38A2, SLC7A5). The Kaplan-Meier curves validated the reliable predictive ability of the prognostic signature in TCGA and two GEO datasets (p < 0.001, p = 0.001, and p = 0.003, respectively). The area under the curve (AUC) of the ROC curves validated the predictive accuracy of the risk model. We constructed a nomogram to predict the survival probability of LUAD, and the calibration curves showed well predictive accuracy. Finally, functional analysis also revealed distinct immune status between high and low GMScore groups in LUAD. Conclusion Our study constructed a GM-related gene signature, and indicated that GMScore could serve as a novel biomarker for predicting patients' survival in LUAD.
- Open Access
- 2 June 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 48 (1) , 1-18
Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma
Excision repair cross‑complementation group 6 like (ERCC6L) has been reported to be upregulated in a variety of malignant tumors and plays a critical oncogenic role. However, the role and molecular mechanism of ERCC6L in lung adenocarcinoma (LUAD) remain unclear, and were therefore investigated in the present study. Clinical data of patients with LUAD were obtained and bioinformatics analysis was performed to investigate the expression characteristics, prognostic value, and biological function of ERCC6L. In addition, cell function experiments were performed to detect the effect of ERCC6L silencing on the biological behavior of LUAD cells. The results revealed that ERCC6L expression was significantly higher in LUAD tissues vs. normal lung tissues and closely associated with nodal invasion, advanced clinical stage and survival in LUAD. Overexpression of ERCC6L was an independent prognostic biomarker of overall survival, progression‑free interval, and disease‑specific survival in patients with LUAD. DNA amplification and low methylation levels of ERCC6L suggested regulation at both the genetic and epigenetic levels. The most significant positive genes co‑expressed with ERCC6L were mainly enriched in the cell cycle signaling pathway. The major functions of ERCC6L in LUAD cells were positively correlated with the cell cycle, DNA damage, DNA repair, proliferation, invasion and epithelial‑mesenchymal transition (EMT). Knockdown of ERCC6L inhibited the proliferative, migratory and invasive abilities of A549 and PC9 cells. It also promoted cell apoptosis, and led to cell cycle arrest in the S phase. ERCC6L may regulate the EMT process through the Wnt/β‑catenin and Wnt/Notch 3 signaling pathways, thus regulating the tumorigenesis and progression of LUAD. The overexpression of ERCC6L may be a biological indicator for the diagnosis and prognosis of LUAD. ERCC6L may be a novel molecular target for the treatment of lung cancer.
- 2 June 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 48 (1) , 1-18
Open AccessOverexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma
Excision repair cross‑complementation group 6 like (ERCC6L) has been reported to be upregulated in a variety of malignant tumors and plays a critical oncogenic role. However, the role and molecular mechanism of ERCC6L in lung adenocarcinoma (LUAD) remain unclear, and were therefore investigated in the present study. Clinical data of patients with LUAD were obtained and bioinformatics analysis was performed to investigate the expression characteristics, prognostic value, and biological function of ERCC6L. In addition, cell function experiments were performed to detect the effect of ERCC6L silencing on the biological behavior of LUAD cells. The results revealed that ERCC6L expression was significantly higher in LUAD tissues vs. normal lung tissues and closely associated with nodal invasion, advanced clinical stage and survival in LUAD. Overexpression of ERCC6L was an independent prognostic biomarker of overall survival, progression‑free interval, and disease‑specific survival in patients with LUAD. DNA amplification and low methylation levels of ERCC6L suggested regulation at both the genetic and epigenetic levels. The most significant positive genes co‑expressed with ERCC6L were mainly enriched in the cell cycle signaling pathway. The major functions of ERCC6L in LUAD cells were positively correlated with the cell cycle, DNA damage, DNA repair, proliferation, invasion and epithelial‑mesenchymal transition (EMT). Knockdown of ERCC6L inhibited the proliferative, migratory and invasive abilities of A549 and PC9 cells. It also promoted cell apoptosis, and led to cell cycle arrest in the S phase. ERCC6L may regulate the EMT process through the Wnt/β‑catenin and Wnt/Notch 3 signaling pathways, thus regulating the tumorigenesis and progression of LUAD. The overexpression of ERCC6L may be a biological indicator for the diagnosis and prognosis of LUAD. ERCC6L may be a novel molecular target for the treatment of lung cancer.
- Open Access
- 28 February 2019
- Published by Wiley in IUBMB Life
- Vol. 71 (7) , 942-955
Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma
Kinesin family member 18A (KIF18A), as a member of the kinesin superfamily, is significantly overexpressed and abnormally functions in various human cancers. But, its expression profiling in the lung adenocarcinoma (LUAD) remains unclear. In the present work, using the data derived from the Cancer Genome Atlas (TCGA), we assessed the expression pattern and prognostic value of KIF18A in LUAD. In addition, we analyzed the underlying mechanism of its gene dysregulation. Experimental and bioinformatic analysis results showed that KIF18A expression was dramatically increased in LUAD tissues compared with the normal counterparts. Moreover, the patients with high KIF18A expression had significantly poorer overall survival (OS) and recurrence‐free survival (RFS). Univariate and multivariate analyses indicated that increased KIF18A expression was independently associated with unfavorable OS and RFS. In addition, by analyzing deep sequencing data from TCGA‐LUAD, we found that KIF18A mutation was detected in 2.6% of LUAD cases, and increased KIF18A expression was associated with genetic amplification rather than DNA methylation. Moreover, gene co‐expression network analysis revealed that a total of 339 KIF18A co‐expressed genes were detected and enriched in several tumor‐related pathways, especially cell cycle. Knockdown of KIF18A significantly inhibited cell proliferation in vitro and in vivo. Furthermore, silencing KIF18A induced LUAD cells apoptosis and arrested the cell cycle in the G2/M phase. KIF18A promotes cell proliferation, inhibits apoptosis, and is a valuable prognostic predictor and potential therapeutic target for the patients with LUAD. © 2019 IUBMB Life, 2019
- 28 February 2019
- Published by Wiley in IUBMB Life
- Vol. 71 (7) , 942-955
Open AccessOverexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma
Kinesin family member 18A (KIF18A), as a member of the kinesin superfamily, is significantly overexpressed and abnormally functions in various human cancers. But, its expression profiling in the lung adenocarcinoma (LUAD) remains unclear. In the present work, using the data derived from the Cancer Genome Atlas (TCGA), we assessed the expression pattern and prognostic value of KIF18A in LUAD. In addition, we analyzed the underlying mechanism of its gene dysregulation. Experimental and bioinformatic analysis results showed that KIF18A expression was dramatically increased in LUAD tissues compared with the normal counterparts. Moreover, the patients with high KIF18A expression had significantly poorer overall survival (OS) and recurrence‐free survival (RFS). Univariate and multivariate analyses indicated that increased KIF18A expression was independently associated with unfavorable OS and RFS. In addition, by analyzing deep sequencing data from TCGA‐LUAD, we found that KIF18A mutation was detected in 2.6% of LUAD cases, and increased KIF18A expression was associated with genetic amplification rather than DNA methylation. Moreover, gene co‐expression network analysis revealed that a total of 339 KIF18A co‐expressed genes were detected and enriched in several tumor‐related pathways, especially cell cycle. Knockdown of KIF18A significantly inhibited cell proliferation in vitro and in vivo. Furthermore, silencing KIF18A induced LUAD cells apoptosis and arrested the cell cycle in the G2/M phase. KIF18A promotes cell proliferation, inhibits apoptosis, and is a valuable prognostic predictor and potential therapeutic target for the patients with LUAD. © 2019 IUBMB Life, 2019
- 10 August 2016
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 65 (03) , 250-254
Modified Transsubxiphoid Thoracoscopic Extended Thymectomy in Patients with Myasthenia Gravis
We developed a new minimally invasive thoracoscopic technique of extended thymectomy for myasthenia gravis by combining a subxiphoid incision with dual costal margin incisions. In our experience of 31 consecutive cases, this procedure provides a good operative view in the neck region and makes verification of the bilateral phrenic nerves easy. All the patients recovered smoothly with less trauma, less bleeding, less complication, and good cosmetic results. This modified transsubxiphoid approach is a satisfactory procedure for performing extended thymectomy in patients with myasthenia gravis.
- 10 August 2016
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 65 (03) , 250-254
Modified Transsubxiphoid Thoracoscopic Extended Thymectomy in Patients with Myasthenia Gravis
We developed a new minimally invasive thoracoscopic technique of extended thymectomy for myasthenia gravis by combining a subxiphoid incision with dual costal margin incisions. In our experience of 31 consecutive cases, this procedure provides a good operative view in the neck region and makes verification of the bilateral phrenic nerves easy. All the patients recovered smoothly with less trauma, less bleeding, less complication, and good cosmetic results. This modified transsubxiphoid approach is a satisfactory procedure for performing extended thymectomy in patients with myasthenia gravis.
- Open Access
- 11 July 2015
- Published by Springer Nature in Diagnostic Pathology
- Vol. 10 (1) , 1-7
Expression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma
The CC chemokine receptor 9 (CCR9) plays an important role in tumorigenesis and metastasis in various cancers. Our previous studies have shown the aberrant expression of CCR9 in non-small cell lung cancer (NSCLC) cell lines, revealing that the CCR9-CCL25 axis modulates cell migration and invasion, and supports cancer cell survival by inhibiting apoptosis in vitro and in vivo. In the present study, we aimed to evaluate the expression and possible prognostic role of CCR9 in lung adenocarcinoma. Immunohistochemical analysis of CCR9 expression was performed on 144 lung adenocarcinoma tissues and 30 adjacent normal lung parenchymal tissues. We assessed the correlation of CCR9 expression with clinicopathological characteristics and the prognosis of lung adenocarcinoma. The expression of CCR9 was increased in lung adenocarcinoma tissue compared with normal lung tissue. Moreover, such an expression was positively correlated with tumor size (p = 0.032), lymph node metastasis (p = 0.002) and advanced TNM stage (p = 0.012). In addition, the patients with negative CCR9 expression exhibited a higher overall survival (OS) compared with those with positive CCR9 expression. Multivariate analysis showed that the CCR9 expression was an independent prognostic factor for the OS of patients with lung adenocarcinoma. We, for the first time, reported that CCR9 could be beneficial in predicting lymph node metastasis, and it might act as a novel prognostic biomarker for lung adenocarcinoma.
- 11 July 2015
- Published by Springer Nature in Diagnostic Pathology
- Vol. 10 (1) , 1-7
Open AccessExpression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma
The CC chemokine receptor 9 (CCR9) plays an important role in tumorigenesis and metastasis in various cancers. Our previous studies have shown the aberrant expression of CCR9 in non-small cell lung cancer (NSCLC) cell lines, revealing that the CCR9-CCL25 axis modulates cell migration and invasion, and supports cancer cell survival by inhibiting apoptosis in vitro and in vivo. In the present study, we aimed to evaluate the expression and possible prognostic role of CCR9 in lung adenocarcinoma. Immunohistochemical analysis of CCR9 expression was performed on 144 lung adenocarcinoma tissues and 30 adjacent normal lung parenchymal tissues. We assessed the correlation of CCR9 expression with clinicopathological characteristics and the prognosis of lung adenocarcinoma. The expression of CCR9 was increased in lung adenocarcinoma tissue compared with normal lung tissue. Moreover, such an expression was positively correlated with tumor size (p = 0.032), lymph node metastasis (p = 0.002) and advanced TNM stage (p = 0.012). In addition, the patients with negative CCR9 expression exhibited a higher overall survival (OS) compared with those with positive CCR9 expression. Multivariate analysis showed that the CCR9 expression was an independent prognostic factor for the OS of patients with lung adenocarcinoma. We, for the first time, reported that CCR9 could be beneficial in predicting lymph node metastasis, and it might act as a novel prognostic biomarker for lung adenocarcinoma.
- 30 April 2013
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 95 (6) , 2028-2034
Keeping Donor Hearts in Completely Beating Status With Normothermic Blood Perfusion for Transplants
- 30 April 2013
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 95 (6) , 2028-2034
Keeping Donor Hearts in Completely Beating Status With Normothermic Blood Perfusion for Transplants